| Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome GW Rhyasen, L Bolanos, J Fang, A Jerez, M Wunderlich, C Rigolino, ... Cancer cell 24 (1), 90-104, 2013 | 211 | 2013 |
| IRAK signalling in cancer GW Rhyasen, DT Starczynowski British journal of cancer 112 (2), 232-237, 2015 | 174 | 2015 |
| AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies GW Rhyasen, MM Hattersley, Y Yao, A Dulak, W Wang, P Petteruti, ... Molecular cancer therapeutics 15 (11), 2563-2574, 2016 | 145 | 2016 |
| Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1 J Fang, G Rhyasen, L Bolanos, C Rasch, M Varney, M Wunderlich, ... Blood, The Journal of the American Society of Hematology 120 (4), 858-867, 2012 | 131 | 2012 |
| Deregulation of microRNAs in myelodysplastic syndrome GW Rhyasen, DT Starczynowski Leukemia 26 (1), 13-22, 2012 | 99 | 2012 |
| OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues M Wunderlich, RA Brooks, R Panchal, GW Rhyasen, G Danet-Desnoyers, ... Blood, The Journal of the American Society of Hematology 123 (24), e134-e144, 2014 | 73 | 2014 |
| BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors GW Rhyasen, Y Yao, J Zhang, A Dulak, L Castriotta, K Jacques, W Zhao, ... PLoS One 13 (7), e0200826, 2018 | 50 | 2018 |
| An MDS xenograft model utilizing a patient-derived cell line GW Rhyasen, M Wunderlich, K Tohyama, G Garcia-Manero, JC Mulloy, ... Leukemia 28 (5), 1142-1145, 2014 | 49 | 2014 |
| Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13 S Imren, M Heuser, M Gasparetto, PA Beer, GL Norddahl, P Xiang, ... Blood, The Journal of the American Society of Hematology 124 (24), 3608-3612, 2014 | 37 | 2014 |
| Differential IRAK signaling in hematologic malignancies GW Rhyasen, L Bolanos, DT Starczynowski Experimental hematology 41 (12), 1005-1007, 2013 | 22 | 2013 |
| Combination therapy for MDS D Starczynowski, GW Rhyasen US Patent 9,855,273, 2018 | 15 | 2018 |
| TNFAIP3 plays a role in aging of the hematopoietic system MA Smith, AE Culver-Cochran, ER Adelman, GW Rhyasen, A Ma, ... Frontiers in immunology 11, 536442, 2020 | 13 | 2020 |
| Combination therapy for MDS D Starczynowski, GW Rhyasen US Patent 9,168,257, 2015 | 13 | 2015 |
| Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety A Fattaey, GW Rhyasen US Patent App. 15/800,386, 2018 | 5 | 2018 |
| The combination of venetoclax and CUDC-907 exhibits synergistic activity in venetoclax-refractory DLBCL K Sun, R Atoyan, MA Borek, S Dellarocca, G Rhyasen, A Fattaey, DP Tuck Blood 128 (22), 4184, 2016 | 4 | 2016 |
| Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome G Rhyasen, L Bolanos, J Fang, C Rigolino, A Cortelezzi, EN Oliva, ... Blood, The Journal of the American Society of Hematology 118 (21), 612-612, 2011 | 2 | 2011 |
| Substituted Imidazo [1, 2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors DT Starczynowski, CJ Thomas, G Rhyasen, K Melgar, MM Walker, ... US Patent 11,542,261, 2023 | 1 | 2023 |
| BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer GW Rhyasen, Y Yao, A Dulak, L Castriotta, K Jacques, M Hattersley, ... Cancer Research 76 (14_Supplement), 1971-1971, 2016 | 1 | 2016 |
| Combination therapy for MDS D STARCZYNOWSKI, GW Rhyasen CA Patent App. 2,907,960 A, 2014 | 1 | 2014 |
| Development and Characterization of a Novel Human Xenograft Model Using an MDS Patient-Derived Cell Line G Rhyasen, M Wunderlich, JC Mulloy, DT Starczynowski Blood 120 (21), 3814, 2012 | 1 | 2012 |
